TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4031995

Group type: EXPERIMENTAL
Intervention: Load-induced perturbations applied to the lower lip during speech tasks.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Load timing variations within the target interval.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Afferent information from the perioral region.
Number of subjects: 5
Study: 30053431

Group type: EXPERIMENTAL
Intervention: Placement of a nurse (TB/HIV integration officer) and a lay health worker (TB screening officer) for 24 months
Number of subjects: 3328
Study: 29691550

Group type: EXPERIMENTAL
Intervention: Titanium ball / titanium cap group (Group A)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Titanium ball / golden cap group (Group B)
Number of subjects: 6
Study: 26053341

Group type: EXPERIMENTAL
Intervention: LISA via a thin catheter
Number of subjects: 211

Group type: COMPARATOR
Intervention: Conventional therapy (endotracheal intubation during mechanical ventilation)
Number of subjects: 211
Study: 23782463

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) added to treatment as usual
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg OD, increased to 40 mg after 4 weeks) added to treatment as usual
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Ondansetron and Simvastatin added to treatment as usual
Number of subjects: 216

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 216
Study: 20230405

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m² on days 1, 3, and 5 (arm A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 6 mg/m² on day 1 and 3 mg/m² on day 8 (arm B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 56
Study: 18986292

Group type: EXPERIMENTAL
Intervention: Blinded intervention in clinical trials for community-acquired pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinded trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinding of clinical trial participants and study drug assignment
Number of subjects: 0
Study: 16902792

Group type: EXPERIMENTAL
Intervention: 40 mg of methylprednisolone injected intramuscularly
Number of subjects: 35

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 35
Study: 12836809

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% and Latanoprost 0.005%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 0.5%/Dorzolamide 2%
Number of subjects: 0
Study: 10806590

Group type: EXPERIMENTAL
Intervention: Highly purified FSH (H.P. FSH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (hMG)
Number of subjects: 20
Study: 9017565

Group type: EXPERIMENTAL
Intervention: Inpatient detoxification
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Previous detox hospitalizations
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Attendance at outpatient programs
Number of subjects: 101

Group type: COMPARATOR
Intervention: Histories of violence, use of drugs, or demographic characteristics
Number of subjects: 101

Group type: COMPARATOR
Intervention: Histories of trauma
Number of subjects: 101
Study: 1705921

Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Future oriented hypnotic imagery
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Self-hypnosis condition
Number of subjects: 55
Study: 6511541

Group type: COMPARATOR
Intervention: Rest group (no training)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise group (20-45 min/day at 50-60% Vo2max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study: 29696328

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle Maneuver (IPM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Pringle Maneuver (NPM)
Number of subjects: 100
Study: 27029628

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both rTMS and CIMT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Camp alone (no rTMS or CIMT)
Number of subjects: 45
Study: 25137864

Group type: EXPERIMENTAL
Intervention: High fidelity simulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low fidelity simulation
Number of subjects: 11
Study: 23544200

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ranibizumab + Laser
Number of subjects: 74
Study: 19669176

Group type: EXPERIMENTAL
Intervention: Tetric Ceram
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram (TEC)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Gradia Direct Posterior
Number of subjects: 49
Study: 18587620

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg SR, BID)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 16998453

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (3 x 1000 mg/day for 8 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (3 x 50 mg/day of glucose for 8 days)
Number of subjects: 24
Study: 15151735

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 microg IM
Number of subjects: 160

Group type: COMPARATOR
Intervention: Oxytocin 10 IU IV infusion
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 11283917

Group type: EXPERIMENTAL
Intervention: 2.0 mg zoledronic acid
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 4.0 mg zoledronic acid
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 90 mg pamidronate
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: 0.4 mg zoledronic acid
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: All treatment groups (including 2.0 mg and 4.0 mg zoledronic acid, and 90 mg pamidronate)
Number of subjects: 280

Group type: COMPARATOR
Intervention: zoledronic acid and pamidronate
Number of subjects: 280
Study: 9276357

Group type: EXPERIMENTAL
Intervention: Radiation plus immediate LHRH agonist (androgen suppression)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Radiation alone with hormonal manipulation at relapse
Number of subjects: 173
Study: 8214504

Group type: EXPERIMENTAL
Intervention: New epidural catheter with three lateral eyes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Current catheter type with three widely spaced lateral eyes
Number of subjects: 200
Study: 2885122

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All beta-adrenoceptor antagonists (except pindolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All beta-adrenoceptor antagonists
Number of subjects: 0
Study: 30612482

Group type: EXPERIMENTAL
Intervention: Betamethasone (intramuscular injection of 12 mg in two doses with an interval of 24 hours)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 240
Study: 30306310

Group type: EXPERIMENTAL
Intervention: HPV vaccination post treatment
Number of subjects: 178

Group type: COMPARATOR
Intervention: Non-vaccination group
Number of subjects: 178
Study: 27753551

Group type: EXPERIMENTAL
Intervention: Sub-dissociative dose (0.2 mg/kg) of IV ketamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 10
Study: 24742341

Group type: EXPERIMENTAL
Intervention: RDN (EnligHTN(TM), SJM system) plus usual care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 240
Study: 23111973

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 40
Study: 20142823

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement (MMS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Calcium 162 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 18592623

Group type: EXPERIMENTAL
Intervention: Radiotherapy treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Demographic characteristics (gender, age, years of education, performance status)
Number of subjects: 82
Study: 15996074

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 12735425

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied to the face
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study: 10233206

Group type: EXPERIMENTAL
Intervention: Modified release verapamil p.o. (240 mg) administered in the morning (08:00 h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Modified release verapamil p.o. (240 mg) administered in the evening (20:00 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deuterated verapamil i.v. (10 mg) administered in the morning
Number of subjects: 24

Group type: COMPARATOR
Intervention: Deuterated verapamil i.v. (10 mg) administered in the evening
Number of subjects: 24
Study: 9005423

Group type: EXPERIMENTAL
Intervention: Cholelithiasis
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Non-ulcer dyspepsia
Number of subjects: 392

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 392
Study: 1924426

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg E5
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg E5
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E5 (2.5 mg/kg and 7.5 mg/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E5
Number of subjects: 23
Study: 6413994

Group type: EXPERIMENTAL
Intervention: Procyclidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30308546

Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 187

Group type: COMPARATOR
Intervention: 2L of polyethylene glycol/ascorbic acid (2L-PEG/Asc)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: OSS
Number of subjects: 187

Group type: COMPARATOR
Intervention: 2L-PEG/Asc
Number of subjects: 187
Study: 28006816

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: cfDNA positivity (cfDNA+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cfDNA detection rates
Number of subjects: 0
Study: 27423195

Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Number of subjects: 56

Group type: COMPARATOR
Intervention: CT Navigation
Number of subjects: 56
Study: 24445092

Group type: EXPERIMENTAL
Intervention: 2.4 mL contrast agent
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 4.8 mL contrast agent
Number of subjects: 51

Group type: COMPARATOR
Intervention: 1.2 mL contrast agent
Number of subjects: 51
Study: 22551576

Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 84
Study: 20447259

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ) 400 mg 3 x per day and amoxicillin (AMX) 500 mg 3 x per day for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with MTZ and AMX
Number of subjects: 30
Study: 18799768

Group type: EXPERIMENTAL
Intervention: 30-minute behavioral intervention
Number of subjects: 924

Group type: COMPARATOR
Intervention: Didactic control condition
Number of subjects: 924
Study: 15990456

Group type: EXPERIMENTAL
Intervention: pegylated IFN α‐2b plus a standard or weight‐based dose of ribavirin
Number of subjects: 50
Study: 11817616

Group type: EXPERIMENTAL
Intervention: Lower extremity exercise performed just prior to depressurization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Longer rest intervals prior to depressurization
Number of subjects: 20
Study: 9887160

Group type: EXPERIMENTAL
Intervention: Behavioral intervention consisting of three small-group sessions (3-4 hours each)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Standard counseling about sexually transmitted diseases (Control)
Number of subjects: 617
Study: 7725889

Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (20 mg) in group A
Number of subjects: 90

Group type: COMPARATOR
Intervention: Meperidine (50 mg) in group A
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clonidine (150 micrograms) in group A
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (10 mg) in group B
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (20 mg) in group C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride in group B
Number of subjects: 90
Study: 1904749

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 200 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 400 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 800 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 1200 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen (all doses)
Number of subjects: 4
Study: 6100880

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg once-a-day
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 31660693

Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS over left DLPFC (20 min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study: 29848108

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 915

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study: 27473924

Group type: EXPERIMENTAL
Intervention: Lexia Reading Core5 intervention (n=49)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waiting-list control group (n=49)
Number of subjects: 98
Study: 24170766

Group type: EXPERIMENTAL
Intervention: 2-hour suspension of basal insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control nights (usual basal rates continued)
Number of subjects: 17
Study: 22988681

Group type: EXPERIMENTAL
Intervention: Gluma (glutaraldehyde‐based desensitizing system)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 22
Study: 20647511

Group type: EXPERIMENTAL
Intervention: Mepilex Lite dressings
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard aqueous cream
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TLD measurements
Number of subjects: 28
Study: 20952606

Group type: EXPERIMENTAL
Intervention: High-flexion posterior-stabilized rotating-platform mobile-bearing prosthesis
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard posterior-stabilized rotating-platform mobile-bearing prosthesis
Number of subjects: 170
Study: 16091060

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 52 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 31
Study: 12359996

Group type: EXPERIMENTAL
Intervention: Forced warm air
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rewarming protocol for hypothermic patients
Number of subjects: 60
Study: 9495581

Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg i.v. twice a day for five days
Number of subjects: 194

Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 194
Study: 7803739

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of protamine (Group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HDRC with correction factor 1.3 (Group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HDRC with correction factor 1.0 (Group III)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 45
Study: 29505145

Group type: EXPERIMENTAL
Intervention: 500,000 IU D3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 250,000 IU D3
Number of subjects: 30
Study: 27488326

Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Concomitant therapy (CT)
Number of subjects: 68
Study: 24357473

Group type: EXPERIMENTAL
Intervention: Low protein intake (<0.8 g/(kg · d))
Number of subjects: 1793

Group type: EXPERIMENTAL
Intervention: Moderate protein intake (0.8-<1.0 g/(kg · d))
Number of subjects: 1793

Group type: EXPERIMENTAL
Intervention: High protein intake (1.0-1.2 g/(kg · d))
Number of subjects: 1793
Study: 23775182

Group type: EXPERIMENTAL
Intervention: Influenza infections in children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Influenza infections in adults
Number of subjects: 0
Study: 20955336

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 18173340

Group type: EXPERIMENTAL
Intervention: One-level arthroplasty with CHARITE artificial disc
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-level fusion with BAK and pedicle screws
Number of subjects: 0
Study: 15985575

Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 50
Study: 12486283

Group type: EXPERIMENTAL
Intervention: IFN beta1a (Avonex or Rebif)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose 6‐methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 0
Study: 10785284

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHO-loading) involving exhaustive one-legged cycling (73+/‐3% of maximal oxygen uptake for 130-160 min) followed by a low-CHO diet for 2-3 days and a high-CHO diet for the next 3 days.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control leg (no CHO-loading).
Number of subjects: 16
Study: 8679359

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ondansetron with dexamethasone (4 mg and 8 mg, respectively)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 100
Study: 1814445

Group type: EXPERIMENTAL
Intervention: Low dosed fluoridated dentifrice (0.085% F)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 100
Study: 6834817

Group type: EXPERIMENTAL
Intervention: Thermal dilution technique
Number of subjects: 40
Study: 30852440

Group type: EXPERIMENTAL
Intervention: Modified bubbles masking paradigm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye-movements measured in conjunction with the bubbles paradigm
Number of subjects: 0
Study: 30531690

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 589
Study: 26796524

Group type: EXPERIMENTAL
Intervention: Flick application before vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual vaccination without flick application)
Number of subjects: 0
Study: 24568227

Group type: EXPERIMENTAL
Intervention: Fatigue protocol consisting of a repeated sprint ability (RSA) test (2 × 15‐m shuttle sprint interspersed with 20 seconds of passive recovery, repeated 6 times)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fatigue protocol consisting of a repeated sprint ability (RSA) test
Number of subjects: 21
Study: 21811829

Group type: EXPERIMENTAL
Intervention: 300 ml warm water instillation (30 °C)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional method without water instillation
Number of subjects: 207
Study: 21344803

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (ITDI), administered once every week for a maximum of three sessions
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 21
Study: 17661541

Group type: EXPERIMENTAL
Intervention: Memantine (Namenda)
Number of subjects: 4
Study: 15643512

Group type: EXPERIMENTAL
Intervention: Paclitaxel (70 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (35 mg/m2) on days 1 and 8 every 3 weeks (GCP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m2 on days 1, 8, 15) and cisplatin (70 mg/m2 on day 2 every 4 weeks (GC)
Number of subjects: 85
Study: 11773916

Group type: EXPERIMENTAL
Intervention: Cigar smoking
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 9438780

Group type: EXPERIMENTAL
Intervention: 10 microg of octreotide (OCT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 25 microg of octreotide (OCT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 50 microg of octreotide (OCT)
Number of subjects: 25
Study: 7867444

Group type: EXPERIMENTAL
Intervention: HD‐Ara‐C (1.0 g/m2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no HD‐Ara‐C therapy)
Number of subjects: 37
Study: 2671475

Group type: EXPERIMENTAL
Intervention: High salt diet (220 mmol/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low salt diet (20 mmol/day)
Number of subjects: 15
Study: 801412

Group type: EXPERIMENTAL
Intervention: Ritodrine HCl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31282394

Group type: EXPERIMENTAL
Intervention: Spinal decompression therapy (SDT) with core stabilization exercises (CSE)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Core stabilization exercises (CSE) alone
Number of subjects: 31
Study: 31300012

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6 mL/kg) in high P/F subgroup (> 150 mmHg)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6 mL/kg) in low P/F subgroup (≤ 150 mmHg)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Traditional tidal volume ventilation in high P/F subgroup (> 150 mmHg)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Traditional tidal volume ventilation in low P/F subgroup (≤ 150 mmHg)
Number of subjects: 836